Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder. Its lead product candidate, ANEB-001, has completed dosing in a Phase 2 clinical trial (www.clinicaltrials.gov/ct2/show/NCT05282797) evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication. ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). For further information about Anebulo, please visit www.anebulo.com.
Company profile
Ticker
ANEB
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
851170950
ANEB stock data
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
13 Feb 24
8-K
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024
13 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
21 Nov 23
10-Q
2024 Q1
Quarterly report
14 Nov 23
8-K
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024
14 Nov 23
ARS
2023 FY
Annual report to shareholders
30 Oct 23
DEF 14A
Definitive proxy
30 Oct 23
PRE 14A
Preliminary proxy
19 Oct 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
8-K
Departure of Directors or Certain Officers
28 Sep 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.52 mm | 8.52 mm | 8.52 mm | 8.52 mm | 8.52 mm | 8.52 mm |
Cash burn (monthly) | 908.94 k | 227.24 k | 847.89 k | 976.27 k | 908.94 k | 864.67 k |
Cash used (since last report) | 5.40 mm | 1.35 mm | 5.04 mm | 5.80 mm | 5.40 mm | 5.14 mm |
Cash remaining | 3.12 mm | 7.17 mm | 3.48 mm | 2.72 mm | 3.12 mm | 3.38 mm |
Runway (months of cash) | 3.4 | 31.6 | 4.1 | 2.8 | 3.4 | 3.9 |
Institutional ownership, Q2 2023
45.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 3 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 16.50 bn |
Total shares | 11.69 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
22NW | 5.07 mm | $11.91 bn |
Aron R. English | 4.65 mm | $0.00 |
LVW Advisors | 672.33 k | $1.58 bn |
Nantahala Capital Management | 511.07 k | $1.20 bn |
Mangrove Partners | 399.22 k | $938.17 mm |
Praetorian PR | 180.01 k | $423.01 mm |
Ikarian Capital | 156.20 k | $340.52 mm |
Boothbay Fund Management | 17.32 k | $40.70 mm |
Vanguard | 16.03 k | $37.68 mm |
BLK Blackrock | 7.25 k | $17.05 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | Cundy Kenneth C | Stock Option Common Stock | Grant | Acquire A | No | No | 2.72 | 72,613 | 197.51 k | 72,613 |
18 Dec 23 | Aron R. English | Common Stock | Gift | Acquire G | Yes | No | 0 | 300,000 | 0.00 | 5,366,290 |
18 Dec 23 | Aron R. English | Common Stock | Gift | Dispose G | Yes | No | 0 | 300,000 | 0.00 | 0 |
13 Nov 23 | Aron R. English | Common Stock | Grant | Acquire A | Yes | No | 0 | 300,000 | 0.00 | 300,000 |
6 Oct 23 | Bimal R. Shah | Stock Option Common Stock | Grant | Acquire A | No | No | 3.0271 | 26,097 | 79.00 k | 26,097 |
News
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
14 Feb 24
Anebulo Pharmaceuticals Q2 EPS $(0.11) Misses $(0.10) Estimate
13 Feb 24
Anebulo Pharmaceuticals Filed U.S. Patent Application #20240010617: Crystalline Forms Of A Cannabinoid Receptor Type 1 (Cb1) Modulator And Methods Of Use And Preparation Thereof
11 Jan 24